STOCK TITAN

[144] Johnson & Johnson SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

Johnson & Johnson (JNJ) filed a Form 144 reporting a proposed sale of 125,824 common shares through Fidelity Brokerage Services with an aggregate market value of $22,652,723.84. The filing states the shares are to be sold on or about 08/22/2025 and that the shares were acquired via an option granted on 02/08/2016, with payment to be cash at sale.

The filer certifies there is no undisclosed material information and indicates no other securities of the issuer were sold by the same person in the past three months. The disclosure documents a sizable, rule-compliant planned insider sale routed through a broker on the NYSE.

Johnson & Johnson (JNJ) ha presentato un Modulo 144 segnalando la proposta di vendita di 125.824 azioni ordinarie tramite Fidelity Brokerage Services per un valore complessivo di mercato di $22.652.723,84. La segnalazione indica che le azioni saranno vendute in data prevista intorno al 22/08/2025 e che sono state acquisite mediante un opzione concessa il 08/02/2016, con pagamento in contanti al momento della vendita.

Il dichiarante certifica che non esistono informazioni materiali non divulgate e precisa che la stessa persona non ha venduto altri titoli dell’emittente negli ultimi tre mesi. La comunicazione documenta una consistente vendita programmata, conforme alle norme, eseguita tramite un broker sulla NYSE.

Johnson & Johnson (JNJ) presentó un Formulario 144 informando de la propuesta de venta de 125.824 acciones ordinarias a través de Fidelity Brokerage Services por un valor de mercado agregado de $22,652,723.84. El documento indica que las acciones se venderán aproximadamente el 22/08/2025 y que fueron adquiridas mediante una opción otorgada el 08/02/2016, con pago en efectivo al momento de la venta.

El declarante certifica que no existe información material no divulgada e indica que la misma persona no vendió otros valores del emisor en los últimos tres meses. La divulgación documenta una venta interna programada de importante magnitud, conforme a las normas, canalizada por un corredor en la NYSE.

Johnson & Johnson (JNJ)가 Form 144를 제출하여 Fidelity Brokerage Services를 통해 125,824 보통주를 총액 $22,652,723.84에 매도할 예정이라고 보고했습니다. 제출서류에 따르면 이 주식은 2025-08-22경 매도될 예정이며, 주식은 2016-02-08에 부여된 옵션으로 취득되었고 매도 시 현금으로 결제될 예정이라고 명시되어 있습니다.

보고인은 공개되지 않은 중요한 정보가 없음을 인증하며, 동일인이 지난 3개월 동안 해당 발행자의 다른 증권을 매도한 바 없음을 표시했습니다. 이 공시는 NYSE의 중개인을 통해 규정에 맞게 처리되는 상당 규모의 내부자 예정 매도를 문서화한 것입니다.

Johnson & Johnson (JNJ) a déposé un Formulaire 144 signalant la vente projetée de 125 824 actions ordinaires via Fidelity Brokerage Services pour une valeur marchande totale de 22 652 723,84 $. Le dépôt indique que les actions seront vendues aux alentours du 22/08/2025 et qu’elles ont été acquises au titre d’une option accordée le 08/02/2016, avec un paiement en espèces lors de la vente.

Le déclarant certifie qu’il n’existe aucune information matérielle non divulguée et précise que la même personne n’a pas vendu d’autres titres de l’émetteur au cours des trois derniers mois. La divulgation documente une vente interne planifiée d’importance, conforme aux règles, effectuée via un courtier sur la NYSE.

Johnson & Johnson (JNJ) hat ein Formular 144 eingereicht und den geplanten Verkauf von 125.824 Stammaktien über Fidelity Brokerage Services mit einem zusammengefassten Marktwert von $22.652.723,84 gemeldet. In der Einreichung heißt es, die Aktien sollen am oder um den 22.08.2025 verkauft werden und wurden durch eine am 08.02.2016 gewährte Option erworben; die Zahlung erfolgt beim Verkauf in Bargeld.

Der Meldende bescheinigt, dass keine nicht offengelegten wesentlichen Informationen vorliegen, und gibt an, dass dieselbe Person in den letzten drei Monaten keine weiteren Wertpapiere des Emittenten verkauft hat. Die Offenlegung dokumentiert einen umfangreichen, regelkonformen geplanten Insiderverkauf über einen Broker an der NYSE.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine, transparent insider sale of 125,824 shares totaling ~$22.7M; neutral but notable for size.

The Form 144 shows an insider selling shares acquired by option exercise in 2016, using Fidelity as broker and receiving cash at sale. The transaction is a standard Rule 144 notification and the filer affirms no material nonpublic information. For investors, the key datapoints are the number of shares and the aggregate value; absent other context about holdings or intent, this disclosure is a neutral liquidity event rather than an operational signal.

TL;DR: Disclosure meets Rule 144 requirements; representation of no undisclosed material info is important for compliance.

The filing documents compliance with securities-law disclosure norms and includes the required representation about material information and any 10b5-1 trading plans. The use of a broker and explicit acquisition details (option grant date) support traceability. This is a governance-positive action insofar as it provides public notice of an insider sale.

Johnson & Johnson (JNJ) ha presentato un Modulo 144 segnalando la proposta di vendita di 125.824 azioni ordinarie tramite Fidelity Brokerage Services per un valore complessivo di mercato di $22.652.723,84. La segnalazione indica che le azioni saranno vendute in data prevista intorno al 22/08/2025 e che sono state acquisite mediante un opzione concessa il 08/02/2016, con pagamento in contanti al momento della vendita.

Il dichiarante certifica che non esistono informazioni materiali non divulgate e precisa che la stessa persona non ha venduto altri titoli dell’emittente negli ultimi tre mesi. La comunicazione documenta una consistente vendita programmata, conforme alle norme, eseguita tramite un broker sulla NYSE.

Johnson & Johnson (JNJ) presentó un Formulario 144 informando de la propuesta de venta de 125.824 acciones ordinarias a través de Fidelity Brokerage Services por un valor de mercado agregado de $22,652,723.84. El documento indica que las acciones se venderán aproximadamente el 22/08/2025 y que fueron adquiridas mediante una opción otorgada el 08/02/2016, con pago en efectivo al momento de la venta.

El declarante certifica que no existe información material no divulgada e indica que la misma persona no vendió otros valores del emisor en los últimos tres meses. La divulgación documenta una venta interna programada de importante magnitud, conforme a las normas, canalizada por un corredor en la NYSE.

Johnson & Johnson (JNJ)가 Form 144를 제출하여 Fidelity Brokerage Services를 통해 125,824 보통주를 총액 $22,652,723.84에 매도할 예정이라고 보고했습니다. 제출서류에 따르면 이 주식은 2025-08-22경 매도될 예정이며, 주식은 2016-02-08에 부여된 옵션으로 취득되었고 매도 시 현금으로 결제될 예정이라고 명시되어 있습니다.

보고인은 공개되지 않은 중요한 정보가 없음을 인증하며, 동일인이 지난 3개월 동안 해당 발행자의 다른 증권을 매도한 바 없음을 표시했습니다. 이 공시는 NYSE의 중개인을 통해 규정에 맞게 처리되는 상당 규모의 내부자 예정 매도를 문서화한 것입니다.

Johnson & Johnson (JNJ) a déposé un Formulaire 144 signalant la vente projetée de 125 824 actions ordinaires via Fidelity Brokerage Services pour une valeur marchande totale de 22 652 723,84 $. Le dépôt indique que les actions seront vendues aux alentours du 22/08/2025 et qu’elles ont été acquises au titre d’une option accordée le 08/02/2016, avec un paiement en espèces lors de la vente.

Le déclarant certifie qu’il n’existe aucune information matérielle non divulguée et précise que la même personne n’a pas vendu d’autres titres de l’émetteur au cours des trois derniers mois. La divulgation documente une vente interne planifiée d’importance, conforme aux règles, effectuée via un courtier sur la NYSE.

Johnson & Johnson (JNJ) hat ein Formular 144 eingereicht und den geplanten Verkauf von 125.824 Stammaktien über Fidelity Brokerage Services mit einem zusammengefassten Marktwert von $22.652.723,84 gemeldet. In der Einreichung heißt es, die Aktien sollen am oder um den 22.08.2025 verkauft werden und wurden durch eine am 08.02.2016 gewährte Option erworben; die Zahlung erfolgt beim Verkauf in Bargeld.

Der Meldende bescheinigt, dass keine nicht offengelegten wesentlichen Informationen vorliegen, und gibt an, dass dieselbe Person in den letzten drei Monaten keine weiteren Wertpapiere des Emittenten verkauft hat. Die Offenlegung dokumentiert einen umfangreichen, regelkonformen geplanten Insiderverkauf über einen Broker an der NYSE.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Johnson & Johnson

NYSE:JNJ

JNJ Rankings

JNJ Latest News

JNJ Latest SEC Filings

JNJ Stock Data

430.71B
2.41B
0.06%
74.35%
0.71%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
NEW BRUNSWICK